|
|
Post by jpg on Jan 13, 2015 8:58:33 GMT -5
Question to anyone (cats, dogs, lizards etc): when are the BofA shares supposed to be returned? Isn't it scheduled for February 2015? 10 million shares if I recall correctly? I thought it when the note was taken care of. It's 9,000,000 or cash vAlue of that Thank you. Yes that would make more sense I guess. JPG |
|
|
|
Post by jpg on Jan 13, 2015 9:30:27 GMT -5
Agreed but time is on our side so the way I see it: the more shorts there are the better when we start having good news. JPG True, JPG, but we've had plenty of good news in the last 9 months and, well..... Hi Baba, I'm on a roll here... As I mentioned somewhere else look back at the little interest analysts had with Lipitor and Gleevec. These are only 2 of many drugs that few pundits saw coming (including Novartis who tried to kill Gleevec repeatedly). The other analogy which comes to mind is Dendreon. As far as I, and a few MDs (oncology and urology) I talked to were concerned, there was a significant flaw in the Dendreon business case (on top of the price). Analysts, Wall Street and investors were all in love with the stock. In the long run it didn't sell because of that 'tiny little flaw' (and the price). The moral of my above rambling is that great biotechs are not, in the long run anyway, created by JP Morgan style conferences but by providing clinically useful tools that are easy to sell to MDs and patients. Short term love (Dendreon) or 'cautious acceptance' (Mannkind) by investors of a company is rather meaningless in the medium to long term. Mannkind will become a platform company and insulin (not exactly a recent discovery) is just one of many drugs that will be reinvented by using Technosphere. JPG |
|
